| Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors KA Schalper, M Carleton, M Zhou, T Chen, Y Feng, SP Huang, AM Walsh, ... Nature medicine 26 (5), 688-692, 2020 | 357 | 2020 |
| Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial RW Naumann, A Hollebecque, T Meyer, MJ Devlin, A Oaknin, J Kerger, ... Journal of Clinical Oncology 37 (31), 2825, 2019 | 349 | 2019 |
| Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 trial SL Topalian, S Bhatia, A Amin, RR Kudchadkar, WH Sharfman, C Lebbé, ... Journal of Clinical Oncology 38 (22), 2476, 2020 | 190 | 2020 |
| Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial RL Ferris, WC Spanos, R Leidner, A Gonçalves, UM Martens, C Kyi, ... Journal for immunotherapy of cancer 9 (6), 2021 | 115 | 2021 |
| Efficacy and safety of nivolumab (Nivo)+ ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358 RW Naumann, A Oaknin, T Meyer, JM Lopez-Picazo, C Lao, YJ Bang, ... Annals of Oncology 30, v898-v899, 2019 | 101 | 2019 |
| Nivolumab (nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358. SL Topalian, S Bhatia, RR Kudchadkar, A Amin, WH Sharfman, C Lebbe, ... Journal of Clinical Oncology 36 (15_suppl), 9505-9505, 2018 | 49 | 2018 |
| A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours KL Aung, AB El-Khoueiry, K Gelmon, B Tran, G Bajaj, B He, T Chen, L Zhu, ... Investigational new drugs 36, 1026-1036, 2018 | 37 | 2018 |
| First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese … T Liu, Y Bai, X Lin, W Li, J Wang, X Zhang, H Pan, C Bai, L Bai, Y Cheng, ... International Journal of Cancer 152 (4), 749-760, 2023 | 16 | 2023 |
| Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (IO) therapy. M Carleton, M Zhou, O De Henau, P Phillips, T Chen, Y Feng, SP Huang, ... Journal of Clinical Oncology 36 (15_suppl), 3025-3025, 2018 | 10 | 2018 |
| Computational Algorithms for Penalized Logistic Regression with Categorical Predictors and Random Effect Logistic Models. T Chen | 3 | 2015 |
| Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer M Carleton, D Feltquate, O De Henau, TP Reilly, T Chen, Y Feng, ... US Patent App. 18/090,570, 2023 | | 2023 |
| Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer RS Michael Carleton, David Feltquate, Olivier De Henau, Timothy Patrick ... US Patent App. 16/768,838, 2021 | | 2021 |
| Relapse-Free Survival (Rfs) As a Surrogate Endpoint for Overall Survival (Os) in Adjuvant Interferon Trials in Patients (Pts) with Resectable Cutaneous Melanoma: an Individual … S Suciu, AMM Eggermont, P Lorigan, J Kirkwood, S Markovic, C Garbe, ... Annals of Oncology 25, iv376, 2014 | | 2014 |
| Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma C Robert, L Thomas, C Garbe, C Lebbe, JF Baurain, A Testori, M Maio, ... European Journal of Cancer 47 (Supplement 1), S657-S658, 2011 | | 2011 |
| 3025 Serum Interleukin 8 (IL-8) May Serve as a Biomarker of Response to Immuno-Oncology (IO) Therapy M Carleton, M Zhou, P Phillips, T Chen, Y Feng, SP Huang, A Walsh, ... | | |
